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abstract
Over the past decade a series of trials of the EORTC Brain Tumor Group (BTG)
has substantially inﬂuenced and shaped the standard-of-care of primary brain
tumors. All these trials were coupled with biological research that has allowed
for better understanding of the biology of these tumors. In glioblastoma, EORTC
trial 26981/22981 conducted jointly with the National Cancer Institute of Canada
Clinical Trials Group showed superiority of concomitant radiochemotherapy with
temozolomide over radiotherapy alone. It also identiﬁed the ﬁrst predictive
marker for beneﬁt from alkylating agent chemotherapy in glioblastoma, the
methylation of the O6-methyl-guanyl-methly-transferase (MGMT) gene promoter. In
another large randomized trial, EORTC 26951, adjuvant chemotherapy in anaplastic
oligodendroglial tumors was investigated. Despite an improvement in progression-
free survival this did not translate into a survival beneﬁt. The third example of
a landmark trial is the EORTC 22845 trial. This trial led by the EORTC Radiation
Oncology Group forms the basis for an expectative approach to patients with low-
grade glioma, as early radiotherapy indeed prolongs time to tumor progression but
with no beneﬁt in overall survival. This trial is the key reference in deciding at what
time in their disease adult patients with low-grade glioma should be irradiated.
* Corresponding author. Wolfgang Wick, MD, Department of Neurooncology, Neurology Clinic & National Center for Tumor
Disease, University of Heidelberg, Im Neuenheimer Feld 400, D-69120 Heidelberg, Germany.
Tel.: +49 6221/56-7075; fax: +49 6221/56-7554. E-mail address: wolfgang.wick@med.uni-heidelberg.de (W. Wick).
1359-6349 © 2012 European Organisation for Research and Treatment of Cancer.Open access under CC BY-NC-ND license.
ejc supplements 10, no. 1 (2012) 20–26 21
Future initiatives will continue to focus on the conduct of controlled trials,
rational academic drug development as well as systematic evaluation of tumor
tissue including biomarker development for personalized therapy. Important lessons
learned in neurooncology are to dare to ask real questions rather than merely rapidly
testing new compounds, and the value of well designed trials, including the presence
of controls, central pathology review, strict radiology protocols and biobanking.
Structurally, the EORTC BTG has evolved into a multidisciplinary group with strong
transatlantic alliances. It has contributed to the maturation of neurooncology within
the oncological sciences.
© 2012 European Organisation for Research and Treatment of Cancer.
1. Examples of twenty-ﬁve years of Brain Tumor
Group (BTG) Trials
1.1. Radiochemotherapy and MGMT in newly diagnosed
glioblastoma
For more than 30 years neurosurgical resection to the
extent safely feasible followed by radiotherapy alone
were the cornerstones of treatment for patients with
glioblastoma. The most relevant prognostic parameters
were age, Karnofsky performance score and extent of
neurosurgical resection. Chemotherapeutic agents, with
the possible exception of nitrosoureas, have shown little
or no activity in malignant glioma patients. It was the
EORTC 26981/22981–National Cancer Institute of Canada
Clinical Trials Group (NCIC) CE.3 trial which for the ﬁrst
time in more than 20 years of neurooncology led to
signiﬁcant and relevant progress in the treatment of
glioblastoma patients and has substantially inﬂuenced
management of glioma in general, and future research
in particular. The major results from the trial are
(i) an increase in the overall survival of glioblastoma
patients − at 2 years 27% of patients treated with
combined radiochemotherapy remained alive compared
to only 10% of patients who were initially treated with
radiotherapy alone, 1 (ii) a relevant proportion of patients
surviving >2−5 years 2 and (iii) the identiﬁcation of a
marker for beneﬁt from temozolomide in brain tumors,
promoter hypermethylation of the repair gene encoding
O6-methyl-guanyl-methyl-transferase (MGMT). 3−5
Concomitant and adjuvant radiochemotherapy with
temozolomide has now become the standard of care
for newly diagnosed glioblastoma worldwide, and the
identiﬁcation of MGMT gene promoter methylation as
the ﬁrst predictivemarker in brain tumors introduced the
concept of personalized oncology into neurooncology.
On a scientiﬁc level it heavily inﬂuenced design and
clinical as well as basic research strategies of brain
tumor trials afterwards. Several translational projects
in addition to the companion project on MGMT have
been successfully conducted. 6−14 From all referenced, 1−14
the health-related quality of life (HRQoL) evaluations 4
and work on a stem cell signature explaining resistance
towards radiochemotherapy 8 best show the range of
science that is done within the framework of the
EORTC BTG.
Immediate follow-up projects that are heavily inspired
by the EORTC 26981/22981 trial are the Radiation
Therapy Oncology Group (RTOG) 05-25/EORTC 26052–
22053 Intergroup trial, which aimed at overcoming
MGMT-mediated resistance and improving outcomes
for the putatively sensitive MGMT-promoter-methylated
patients by an intensiﬁed three out of four weeks dose-
dense temozolomide maintenance therapy regimen. This
trial, including over 1100 patients in North America
and Europe, failed to demonstrate an advantage in
PFS or OS. 15 Importantly, the trial showed the feasibility
of international collaboration and mandatory tumor
tissue collection and testing of molecular markers. It
allowed prospective conﬁrmation of the prognostic value
of MGMT promoter methylation. Nevertheless, until
more effective treatments have been developed, outside
clinical trials the EORTC regimen of radiotherapy with
concomitant and adjuvant temozolomide remains the
standard of care for all newly diagnosed glioblastoma.We
recently completed accrual of a large randomized clinical
trial adding the antiangiogenic and anti-migratory inte-
grin inhibitor cilengitide in patients with a methylated
MGMT promoter only (EORTC trial 26071/22072).
When the pivotal glioblastoma trial was designed, an
upper age limit of 70 years was deemed appropriate,
because a prolonged course of therapy would only
jeopardize the quality of life of elderly patients without
sufﬁcient prospect of meaningful beneﬁt. However, the
success of combined modality therapy in younger
patients has led to revisiting this position, and the on-
going NCIC CE.6/EORTC 26062–22061 trial is investigating
combined temozolomide chemotherapy in conjunction
with hypofractionated radiotherapy.
1.2. Molecular subtypes in anaplastic glioma
The EORTC 26951 trial investigating adjuvant procar-
bazine/lomustine/vincristine (PCV) chemotherapy after
completion of radiotherapy in the more chemosen-
sitive anaplastic oligodendroglioma (AOD) and oligo-
astrocytoma (AOA) is another example of a trial that
moved the ﬁeld beyond its actual result. The trials did
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not show a statistically signiﬁcant difference in survival,
although progression-free survival was signiﬁcantly
prolonged. We concluded that chemotherapy has a
clear role in this disease. However, the timing of
administration, initially/adjuvant or at the time of tumor
recurrence or progression, appears of lesser importance,
and toxicity of the chemotherapy has to be taken into
account.
In addition to the publication of the clinical data, 16,17
this study inspired a large series of translational research
efforts which contributed to the molecular subtyping
of anaplastic gliomas 16−22 Together with contemporary
trials of the RTOG (94-02) 23 and the Neurooncology
Working Group of the German Cancer Society (NOA-04), 24
as well as basic research from the International
Cancer Genome Consortium, 25 molecular markers like
MGMT, 21 isocitrate dehydrogenase 1 (IDH1) 20 and co-
deletion 1p/19q 16,19 have been ﬁrmly established in
anaplastic gliomas. Ongoing research aims at unraveling
the ﬁndings in the NOA-04 and EORTC 26951 trials
indicating that MGMT methylation could predict a good
response not only to alkylating chemotherapy but also
to radiotherapy alone. The most recent contribution
here is the strong prognostic effect of the Glioma CpG
Island Methylator Phenotype (G-CIMP) in EORTC 26951
whose clinical signiﬁcance is currently being further
investigated. 26
So far however, all molecular markers in this trial
are merely prognostic. MGMT that has been shown to
be associated with beneﬁt from temozolomide chemo-
therapy in glioblastoma does not hold the predictive
power for alkylating chemotherapy in grade III tumors.
This underscores the distinct biology of anaplastic
tumors and glioblastoma. The need for a molecular
classiﬁcation, especially for anaplastic glioma, was
also emphasized by the intrinsic typing and grading
difﬁculties in these tumors that was addressed in a
post hoc panel review for this trial. 27 This is a topic
of high clinical relevance, with a major impact on
ongoing trials. Recent news on the molecular markers
for oligodendroglioma from US groups is the discovery of
the genes located on 1p and 19q that may be the drivers
for combined loss of 1p/19q in these tumors. Inactivating
mutations have been identiﬁed in far-upstream element
(FUSE) binding protein 1 (FUBP1) [>10% of cases], which
may lead to myc activation, and in homolog of the
Drosophila capicua gene (CIC) [40−50% of cases], which is a
downstream target for some tyrosine kinase receptors. 25
In summary, anaplastic gliomas are regarded as an
important and biologically distinct entity, in which
we made rapid progress in understanding of their
biology and subgroups. Radiotherapy or temozolomide
chemotherapy but not the combination of both is
standard or common practice within the centers of our
group.
Furthermore, this trial with its companions stimulated
two EORTC/RTOG (NCIC/MRC/HUB/NOA/COGNO transat-
lantic intergroup trials (EORTC 26053/22054 [CATNON]
and EORTC 26081/22086 [CODEL]) aiming at answering
another relevant question; determining how to optimally
combine temozolomide chemotherapy and radiotherapy
in anaplastic gliomas, in a joint and therefore more
timely fashion. Clinically, the CATNON trial may also
shed light on the question whether concomitant or
maintenance temozolomide treatment is pivotal for the
success of radiochemotherapy, and thus potentially inﬂu-
ence treatment schedules and future trial development.
In addition, these trials will provide the neurooncological
community with unique biomaterial resources as both
trials rely on the examination of 1p/19q deletion status
as entry criterion and hence biomaterial will also
be available later on for novel translational research
questions.
In order to conduct this important biological research,
we have created a translational research platform
within the EORTC. The advantages of this organized
collaborative effort are evident: not only does it allow
investigation of rare tumor types and subtypes with
characteristic molecular aberrations, but all samples
have been histopathologically reviewed, are annotated
bothmolecularly and clinically, and patients were treated
in a homogeneous manner allowing correlation of
biological ﬁndings with outcome. But to successfully
conduct this type of translational research, we depend
on grant support from both national and international
sources. Collaborations and further expansion of the
translational research expertise within the BTG are key.
When treating patients, quality of life is as much
a concern as simple longevity. Analysis of the HRQOL
data from the EORTC 26981 and 26951 trials showed
that the addition of chemotherapy has no or only a
limited and transient negative impact on HRQOL during
and shortly following treatment. 4,17,28 Not unexpectedly,
the generally well tolerated temozolomide chemotherapy
had a less negative impact than the PCV regimen. Base-
line HRQOL data demonstrated no additional prognostic
signiﬁcance compared to clinical data. Future studies
should include longitudinal HRQOL measurements,
especially following radiological recurrence, to establish
the clinical impact of radiological progression. From the
patient’s perspective, time to clinical deterioration may
be a more relevant endpoint than time to progression
if this progression is still asymptomatic. To meet this
requirement, the validation of novel and more clinical
endpoints is required.
1.3. To believe or not to believe: impact of tumor-speciﬁc
treatment in low-grade glioma
The last example of a landmark EORTC trial conducted
jointly by the Radiation Oncology Group and the BTG is
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the EORTC trial 22845. 29−34 This trial is the key reference
in determining at what time in their disease adult
patients with low-grade glioma should be irradiated. The
trial convincingly demonstrated that adjuvant irradiation
may be delayed until subsequent disease progression
without detrimental effect on overall survival despite
a prolongation in progression-free survival. 29,30 To date
these data, together with the set of prognostic factors
that was established using data from that trial, 31 guide
the decision on when to treat patients with low-grade
tumors. These factors include tumor progression, age
>40 years, presence of neurological deﬁcits other than
only seizures, a tumor size >5 cm or a tumor extending
over the midline. As patients with low-grade gliomas
have a comparably good life expectancy of >7 years and
may survive relevant adverse effects of early therapies,
this information is pivotal. Furthermore, this trial is
one of the very few examples of completed randomized
trials in that disease, in part because of the rarity
and relatively good prognosis and thus long survival of
these patients. Together with the work on temozolomide
in glioblastoma and the increasing awareness in our
group that tissue is the key for academic neurooncology,
this trial also stimulated the important and timely
EORTC 22033-26033 trial that has recently completed its
accrual. In that trial we are asking the question whether
standard ﬁrst-line radiotherapy may be delayed and
replaced by dose-dense temozolomide chemotherapy.
Again tumor tissue has been collected from all patients
and should ultimately allow separation of good- and
poor-prognosis patients based on molecular proﬁles.
Respective molecular signatures may also allow for
identiﬁcation of novel treatment targets.
Until results of this trial are available, the BTG
decided to pursue a new avenue by developing a
trial for recurrent, poor-prognosis, contrast enhancing
low-grade and anaplastic gliomas. In this trial, EORTC
26091/TAVAREC, patients are randomized at progression
after initial treatment to receive temozolomide or
temozolomide plus bevacizumab. With this and the
companion trial 26101 on glioblastoma, the BTG is
not only contributing to the ﬁrst controlled trials with
bevacizumab in recurrent glioma but is also paving the
way for systematic academic centralized evaluation of
imaging. The BTG together with the EORTC Imaging
Platform have set up a standard imaging protocol for
these trials, and data will be assessed centrally in
order to generate pivotal data on the determination of
progression also in the context of antiangiogenic therapy,
recurrence patterns, and an upfront validation of the
updated imaging criteria as developed by the Response
Assessment in Neurooncology (RANO)Working group. 35
2. Towards a molecular classiﬁcation of brain
tumors − prime time for targeted treatments?
Molecular diagnostics of gliomas allows deﬁnition of
more homogeneous patient populations as exempliﬁed
in CODEL and CATNON for anaplastic gliomas with
and without the 1p/19q co-deletion, respectively, the
TAVAREC trial for recurrent glioma, or CENTRIC for
glioblastoma with methylated MGMT. In the future,
molecular diagnostics will be used to test whether
speciﬁc treatments are active depending on the absence
or presence of a speciﬁc molecular marker. In addition,
the determination of IDH mutations is likely to gain an
important role in the near future. Malignant gliomas with
IDH mutations have a much better prognosis and are
thought to have a different pathogenetic origin, further
supported by the recent discovery of G-CIMP associated
with IDH mutations. 26,36 IDH mutations have also been
identiﬁed in acute myeloblastic leukemia in association
with CIMP, and deﬁne a new prognostic subtype (PMID:
21130701; 20567020). Hence, gliomapatients with G-CIMP
are molecularly and biologically distinct and should
probably not be included in future glioblastoma trials.
Biomarker research should provide guidance for
clinical decision making aiming towards personalized
oncology. To date, none of the molecular markers
established in glioma today, e.g. p53, EGFR ampliﬁcation
or autoactivity, 1p/19q co-deletion, MGMT or IDH1/2, are
relevantly contributing to daily decision making.
3. Visions in neurooncology
Classiﬁcation of brain tumors will no longer rely
solely on morphological criteria, but invariably also
include reproducible and standardized [sic!] molecular
markers. For a growing number of patients in industrial
countries sequencing of the full tumor genome is
now available for a couple of hundred euros, and is
becoming more and more affordable. However, we need
to identify mutations that are actionable in glioma in
order to offer appropriate treatments. A genome-wide
expression analysis is done to enable classiﬁcation of
molecular subtypes of strong prognostic relevance. 37
These analyses are currently best performed within
phase II and III clinical trials, however they are
already offered commercially. Diagnostic determination
of molecular signatures should assist choice of therapy
and predict efﬁcacy of established or new therapies, and
will allow to enrich patient population most likely to
beneﬁt from a new treatment, thus avoiding exposure
of a large number of patients to ineffective therapy.
Since the EORTC is dedicated to rational academic drug
development, our trials are designed with a clear focus
on relevance for the patients. Too artiﬁcial inclusion
and exclusion criteria are avoided, which allows an easy
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translation into daily clinical practice and with a clear
focus on non-metric factors such as symptom burden,
tolerance and quality of life aiming to produce relevant
and just signiﬁcant results.
Given present demographics, future trial activities will
focus on the distinct demands of elderly patients. An
older age of tumor patient in general is associated
with increased toxicity of many drugs, including
antineoplastic agents, but increased toxicity in older
patients has also been documented for targeted agents.
Most likely, some of these trials will be carried out
in close collaboration with other cooperative groups as
successfully demonstrated in the past. This demands not
only good scientiﬁc interaction but also a strong political
will to facilitate these projects.
4. EORTC BTG in 2022
We will have learned to recognize and treat the tumor as
an organ.
We will recognize the tumor within its unique
environment and interaction with the host organ. A
tumor exceeds the mere assembly of tumor cells
and requires a permissive milieu provided by non-
malignant cells and structures of the body to grow
and spread. These are in particular vascular, immune
and parenchymal cells 38 and potentially effects of
intercellular plasticity. These components are different in
the brain compared to other compartments of the body.
The obligatory role of non-neoplastic cells is of special
importance to brain tumors since all systemically given
therapies need to reach the tumor cell at sufﬁcient con-
centrations. In addition, immunotherapy, which needs
to overcome the immunosuppressive environment in an
immune-privileged organ, needs further development.
However, smaller immunotherapy trials show promising
molecular signals, which in the future may be translated
into a clinically relevant signal, 39 for example by a future
EORTC trial with an anti-EGFRvIII immunotherapy.
Finally, tumor-initiating cells will be speciﬁcally tar-
geted by the treatment. They will be characterized in
many solid tumors including glioma that will foster the
understanding of therapy resistance. We are prepared
for a paradigm shift, as these cells may be much less
susceptible to classical cytostatic/cytotoxic therapies.
Approaches to modify stem cell features in brain tumors
without heavy interference with physiological systems
will need to be developed.
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